Clinical Trial Update: Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE) [Phase 3]

View source ↗

Summary

Phase 3 trial results for alirocumab in statin-intolerant patients with primary hypercholesterolemia and high cardiovascular risk have been completed with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Hypercholesterolemia

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2015-08-28